In the relentless pursuit of the perfect physique, the bodybuilding world is constantly exploring the next evolutionary stage in enhancing athletic performance and body shape. While anabolic steroids (AAS) and selective androgen receptor modulators (SARMs) have long dominated, a new class of drugs originating from cutting-edge metabolic research is emerging. Among them, madutide (also known as IBI362 or LY3305677) is not a traditional anabolic agent, but a complex multi-target peptide hormone analog. Its application in bodybuilding is still in its nascent stage, falling under off-label use and highly exploratory, thus requiring a detailed, evidence-based explanation, focusing on its main design and potential theoretical benefits.
What is Madutide?
Madutide is neither a steroid nor a SARM. It is a first-in-class, long-acting dual agonist that simultaneously activates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors. Originally developed in collaboration between Innovent Biologics and Eli Lilly, its primary research applications are the treatment of obesity and type 2 diabetes. Chemically, it is a fusion peptide-a genetically engineered single molecule that simultaneously activates two key metabolic pathways. It is a synthetic analog that mimics the effects of the natural incretin hormones GLP-1 and GIP. Through fatty acid chain modification, its half-life is extended, allowing for once-weekly subcutaneous injection, a stark contrast to many other peptide drugs that require daily administration.
How does madutide work?
Madutide is a dual glucagon-like peptide-1 receptor agonist (GLP-1RA) and glucagon receptor agonist, the first of its kind. It helps regulate appetite, metabolism, and improve glycemic control by simultaneously activating both the GLP-1 receptor and the glucagon receptor. This dual action is promising, but further clinical trials are needed to validate its efficacy.
GLP-1 receptors are widely distributed in pancreatic β-cells, the brain, and other tissues. Their mechanism of action includes enhancing insulin secretion, thereby participating in the regulation of blood glucose levels. GLP-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes because they stimulate insulin synthesis and secretion in a glucose-dependent manner, leading to weight loss. Furthermore, they delay gastric emptying, regulate lipid metabolism, reduce fat deposition, and have neuroprotective, anti-infective, and cardiovascular protective effects.
Using glucagon receptor agonists alone is not an ideal treatment option because they increase hepatic glucose production. However, when used in combination with GLP-1 receptor agonists, they can effectively reduce fat mass and improve glucose tolerance.
What are the side effects of madutide?
Clinical reports to date show that madutide is well-tolerated with mild side effects, such as:
Upper respiratory tract infection, diarrhea, nausea, urinary tract infection, abdominal distension, and vomiting.
How to order?
First, please inform us of your needs or application scenario.
Second, we will provide a quotation based on your needs or our suggestions.
Third, the customer confirms the sample and pays a deposit.
Fourth, we will arrange production. Discounts are available for bulk orders.
How is the quality of your products? First of all, our products are of excellent and consistent quality. We conduct 100% testing before shipment.
Therefore, we implement strict quality control before shipment. If any quality issues are found to be caused by us, we will replace the product free of charge or provide a refund.
How to establish a long-term, positive partnership with us?
1. We insist on providing high-quality products and competitive prices to ensure customer benefits;
2. We respect every customer, treat them as friends, and sincerely do business and make friends with them, no matter where they come from.
Hot Tags: high-purity peptide drug mazdutide 5mg/vial, China high-purity peptide drug mazdutide 5mg/vial manufacturers, suppliers, factory
